BREAST DISEASE SITE AGENDA

May 3, 2014

NCIC CLINICAL TRIALS GROUP

DISEASE SITE COMMITTEE MEETING AGENDA

Eaton Chelsea Hotel, Toronto, Ontario
Room: Mountbatten Salon Saturday, May 3, 2014: 8:00 AM – 2:30 PM
CO-CHAIRS: T. WHELAN / K. GELMON

CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:
• To understand and address, through clinical and translational research, the disease burden associated with breast cancer both in the adjuvant and the metastatic setting in Canada
• To review recent developments in the understanding of molecular biology, new therapeutics and clinical trial methodology as these relate to breast cancer
• To update, review, and discuss recent results of clinical studies conducted by or in collaboration with NCIC Clinical Trials Group
• To place the results of clinical studies in the context of ongoing care of patients in Canada with breast cancer and to translate these results into clinical practice
• To provide a learning environment supportive to investigators
• To provide mentoring opportunities for investigators new to clinical research

8:00am Welcome: Review of Objectives T.Whelan/K.Gelmon
8:05am Current Status of Reorganization of Cooperative Groups T.Whelan

8:15am Proposals

CTEP Proposals
• ALTERNATE Trial (Clinical Stage II/III ER+ NeoAdjuvant ) K.Gelmon/M.Clemons
• SWOG 1207 (Phase III Endocrine Therapy +/- Everolimus, High Risk) K.Gelmon
• PENEOPE B (Palbociclib + Standard Endocrine Tx in HR+/Her2 Normal With Residual Disease After Neoadjuvant Chemo & Surgery) K.Gelmon
• Weight Loss trial in early stage breast cancer P.Goodwin

BIG Proposals
• Olympia (Olaparib Early Breast Cancer Adjuvant study - MA.36) A. Eisen
• Neo-Olympia (Olaparib in neoadjuvant TNBC patients) K.Gelmon
• ABCSG - PALLAS (Adjuvant Palbociclib Trial) K.Gelmon

NCIC CTG Proposals
• MA.35 Regional Radiotherapy in Women with Early Breast Cancer Treated by Breast Conserving Surgery and Sentinel Lymph Node Biopsy Alone, with Minimal Nodal Disease T.Whelan/I.Kong/T.Berrang/V.Theberge
9:45am **Status Update of proposals from 2013MAR28 Retreat**

- Randomized Phase II Pre-Operative Trial Comparing 2 Different Doses of the CDK4/6 Inhibitor PF0332991 as well as PF0332991 to Letrozole in Operable or Inoperable Locally Advanced ER+ Breast Cancer  
  M.Basik

- A Phase II Feasibility Study of Stereotactic Body Radiotherapy (SBRT) in the Management of Oligometastatic and Oligoprogresive Breast Cancer Patients  
  T.Whelan

- Pragmatic Study of de-Escalated (q 12 wks) Versus Standard (q 3-4 wks) Bone-Targeted Agents in Bone Metastases (The DeBaTe Study)  
  K.Gelmon/M.Clemons

- **PAthological Complete response Tailored Trastuzumab Treatment (PACT)**  
  K.Gelmon /S.Verma

10:15am **Metastatic Trials and NCIC CTG**

- E2112  A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer  
  K.Gelmon

10:30am Coffee……………………………………………………………………………………………………

10:45am **Report from May 2nd Neoadjuvant Workshop**  
  M.Basik/P.Bedard

11:00am **IND Trials:**

- IND.213 (Phase II Reolysin/Paclitaxel in Advanced/Metastatic)  
  S.Ellard/V.Bernstein

11:15am **Open Trials:**

- MA.33 (TROG 07.01: Non-low risk DCIS of breast)  
  I.Olivotto

11:20am **Invited Speaker : Angela DeMichele MD MSCE,**

**“The I-SPY2 TRIAL: Early Results Evaluating New Agents for Breast Cancer”**

12:00 Noon Lunch……………………………………………………………………………………………………

1:30pm **CTSU Trials:**

- MAC.14 (ECOG 2108 – Local Therapy in Stage IV)  
  M.Basik

- MAC.15 (SWOG S1007 – Responder Trial)  
  S.Chia/B.Dhesy

1:45pm **Closed Trials:**

- MA.17R (Letrozole vs Placebo after AI)  
  W.Parulekar

- MA.20  (Regional Radiation Therapy in Early Breast Cancer)  
  T. Whelan

- MA.32 (Metformin + NSABP Fatigue MA.32F + Alliance Breast Density)  
  P.Goodwin/W.Parulekar

- MA.34  (BIG 4-11/APHINTITY/Pertuzumab)  
  S.Dent

2:15pm **ASCO Update - Breast**  
  L.Shepherd

2:25pm **Closing Remarks and Adjournment**